FindTrial
Sign In

Long Acting Insulin Versus Multiple Dose Regimen for Control of Gestational Diabetes Mellitus

Comparative Study Between Use of Long Acting Insulin Versus Multiple Dose Regimen in Control of Gestational Diabetes Mellitus

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04674332
Enrollment
148
Registered
2020-12-19
Start date
2019-09-01
Completion date
2020-12-14
Last updated
2021-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long Acting Insulin in Control of Gestational Diabetes Mellitus

Brief summary

multiple dose regimen as a standard treatment for gestational diabetes will be compared to long acting insulin

Interventions

DRUGLong acting insulin

long acting insulin analogue once daily at bed time

DRUGmultiple dose regimen

intermediate and short acting insulin

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* pregnant women with gestational diabetes mellitus * between 24-28 weeks gestation

Exclusion criteria

* other endocrinological abnormalities

Design outcomes

Primary

MeasureTime frameDescription
time needed to achieve glycemic control1 yearglycemic control assessed by fasting and postprandial blood sugar

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026